Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

5:15 PM ET 10-Q
Financial Results Keenova Therapeutics plc

Keenova Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Narrows

Keenova Therapeutics reported net sales of $549.5 million for the quarter ended September 30, 2026, a significant increase from $416.1 million in the prior year. Despite higher revenue, the company recorded a net loss of $96.1 million for the quarter and $430.1 million for the nine-month period, primarily driven by a $150.6 million loss on divestiture and $207.7 million in non-restructuring impairment charges.

Key figure
Net loss $96.1M
5:12 PM ET 10-Q
Financial Results GrowGeneration Corp. GRWG

GrowGeneration Q3 2026 Results: Turns Profitable, Net Income $237K

GrowGeneration Corp. reported a net income of $0.2 million for the third quarter of 2026, a significant improvement from a $2.4 million loss in the prior year, despite a 5.2% decline in net sales to $44.8 million. The company reduced its nine-month operating loss from $18.0 million to $7.7 million through substantial reductions in store operations and depreciation expenses.

Key figure
Net income $237K
5:11 PM ET 10-Q
Financial Results International Tower Hill Mines Ltd THM

International Tower Hill Mines Q3 2026 Results: Net Loss of $4.16M, Loss Widens

International Tower Hill Mines Ltd. reported a net loss of $5.3 million for the nine months ended September 30, 2026, compared to $3.3 million in the prior year, primarily driven by a significant increase in mineral property exploration expenses. The company's cash position strengthened substantially to $56.2 million following share issuances, while total assets grew to $164.1 million.

Key figure
Net loss $4.16M
5:11 PM ET 10-Q
Financial Results Actelis Networks Inc ASNS

Actelis Networks Q3 2026 Results: Net Loss of $1.25M, Loss Narrows

Actelis Networks reported a net loss of $5.1 million for the nine months ended September 30, 2026, with an accumulated deficit increasing to $57.4 million. While cash and cash equivalents rose to $4.8 million following equity financing activities, the company continues to highlight its need for additional capital and its status as a going concern.

Key figure
Net loss $1.25M
5:10 PM ET 10-Q
Financial Results Eastern Co EML ▶ Call

Eastern Q3 2026 Results: Net Income $3.45M, Up 495.2% YoY

The Eastern Company reported a significant increase in net income for the third quarter of 2026, reaching $3.4 million compared to $0.6 million in the prior year period, driven by a 35% increase in net sales. For the nine-month period, net income was bolstered by a $6.5 million bargain purchase gain from an acquisition, resulting in total net income of $9.7 million.

Key figure
Net income $3.45M · +495.2% YoY
5:09 PM ET 8-K
Financial Results Sanuwave Health, Inc. SNWV

Sanuwave Health Financial Results

SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.

Term
Q3 2026

“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”

Morgan Frank, CEO
5:07 PM ET 8-K
Financial Results Cumberland Pharmaceuticals Inc CPIX

Cumberland Pharmaceuticals Financial Results

Cumberland Pharmaceuticals reported Q3 2026 financial results, its first full quarter as a development-focused company following the $100 million divestiture of its commercial brands to Apotex Health. The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) following a successful Phase 2 trial.

Term
Q3 2026

“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline. Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”

A.J. Kazimi, CEO of Cumberland Pharmaceuticals
5:07 PM ET 10-Q
Financial Results Mercury Systems Inc MRCY

Mercury Systems Q1 2026 Results: Turns Profitable, Net Income $13.1M

Mercury Systems reported net revenues of $253.2 million for the first quarter ended October 2, 2026, a significant increase from $225.2 million in the prior year. The company achieved a net income of $13.1 million, rebounding from a net loss of $12.5 million in the same period last year, driven by improved gross margins and lower operating expenses.

Key figure
Net income $13.1M
5:07 PM ET 10-Q
Financial Results Suja Life, Inc. SUJA

Suja Life Q3 2026 Results: Net Loss of $5.25M

Suja Life, Inc. completed its IPO on May 8, 2026, raising net proceeds of $173.6 million used primarily for debt repayment and incentive unit settlements. For the nine months ended September 28, 2026, net sales grew to $267.3 million from $236.5 million year-over-year, though the company reported a net loss of $28.4 million driven by transaction costs and debt extinguishment.

Key figure
Net loss $5.25M
5:06 PM ET 10-Q
Financial Results Sunrise Realty Trust, Inc. SUNS

Sunrise Realty Trust Q3 2026 Results: Net Income $2.88M, Down 28.9% YoY

Sunrise Realty Trust reported net income of $2.88 million for the quarter ended September 30, 2026, a decrease from $4.05 million in the prior year period, primarily due to higher interest expenses and merger-related costs. Total assets decreased to $285.4 million from $310.2 million at year-end 2025, while the company maintained a quarterly dividend of $0.30 per share.

Key figure
Net income $2.88M · -28.9% YoY
5:05 PM ET 10-Q
Financial Results Spire Global, Inc. SPIR

Spire Global Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Spire Global reported revenue of $18.0 million for the third quarter of 2026, an increase from $12.7 million in the prior year period. Despite the quarterly growth, the company recorded a net loss for the nine months ended September 30, 2026, contributing to an accumulated deficit of $553.4 million.

Key figure
Net loss $20.3M
5:02 PM ET 10-Q
Financial Results Evolv Technologies Holdings, Inc. EVLV

Evolv Technologies Holdings Q3 2026 Results: Net Loss of $15.6M, Loss Widens

For the nine months ended September 30, 2026, Evolv Technologies reported total revenue of $137.4 million, a 28% increase compared to the same period in 2025. The company reduced its net loss to $29.9 million from $44.0 million year-over-year, driven by improved gross margins and a significant increase in product revenue.

Key figure
Net loss $15.6M
5:01 PM ET 10-Q
Financial Results West Bay BDC LLC

West Bay BDC Q3 2026 Results: Net Income $7.61M, Up 328.6% YoY

For the nine months ended September 30, 2026, West Bay BDC LLC reported total investment income of $38.18 million and net investment income of $19.71 million, a significant increase from the prior year. Total members' capital grew to $319.81 million as of September 30, 2026, driven by common unit issuances and operational performance, while net asset value per unit increased to $17.57.

Key figure
Net income $7.61M · +328.6% YoY
5:01 PM ET 10-Q
Financial Results Phillip Street BDC LLC

Phillip Street BDC Q3 2026 Results: Net Income $11.8M, Up 6.4% YoY

For the nine months ended September 30, 2026, Phillip Street BDC LLC reported total investment income of $67.6 million and net investment income of $38.3 million. Total members' capital increased to $572.1 million, with a net asset value per unit of $20.12, up from $19.83 at the end of 2025.

Key figure
Net income $11.8M · +6.4% YoY
5:01 PM ET 10-Q
Financial Results Elutia Inc. ELUT

Elutia Q3 2026 Results: Net Loss of $1.28M, Loss Narrows

Elutia Inc. is focusing on the development of its next-generation biologic scaffolds, NXT-41 and NXT-41x, following the divestiture of its SimpliDerm and Orthobiologics businesses. The company is managing ongoing litigation related to its FiberCel and VBM product recalls while navigating capital requirements and Nasdaq compliance.

Key figure
Net loss $1.28M
5:01 PM ET 10-Q
Financial Results Silver Capital Holdings LLC

Silver Capital Holdings Q3 2026 Results: Net Loss of $10.9M

Silver Capital Holdings LLC reported a net decrease in net assets resulting from operations of $17.93 million for the nine months ended September 30, 2026, primarily driven by $37.98 million in net unrealized depreciation. Total investment income decreased significantly to $18.98 million from $44.22 million in the prior year period, while the company's net asset value per unit fell to $18.62 from $21.46 at year-end 2025.

Key figure
Net loss $10.9M
5:01 PM ET 8-K
Financial Results Eastern Co EML

Eastern Financial Results

The Eastern Company reported a 36% year-over-year increase in net sales to $75.0 million for the third quarter of 2026, driven by organic growth in truck mirror assemblies and the first full quarter of contributions from Sungear and Crown Precision. Net income from continuing operations rose significantly to $3.4 million, or $0.57 per diluted share, while the company's backlog grew 70% to $126.1 million. Management highlighted the benefits of restructuring initiatives and improved demand across aerospace, defense, and commercial transportation markets.

Term
Q3 2026

“The third quarter showed what Eastern can deliver when the benefits of our restructuring initiatives implemented over the past year are combined with improving demand.”

Ryan Schroeder, Eastern’s President and CEO

“Our job from here is execution: convert the backlog, protect our margins, and stay disciplined on capital, including acquisitions that complement our core strengths and enhance long-term value.”

Ryan Schroeder, Eastern’s President and CEO
5:01 PM ET 10-Q
Financial Results Stellar V Capital Corp. (Cayman Islands) SVCC

Stellar V Capital Q3 2026 Results: Net Income $936K, Down 37.4% YoY

Stellar V Capital Corp. reported a net income of $2.96 million for the nine months ended September 30, 2026, primarily driven by $4.24 million in interest earned on marketable securities held in the Trust Account. The company remains a shell entity with $160.97 million in Class A ordinary shares subject to possible redemption and is actively seeking a target for its initial business combination.

Key figure
Net income $936K · -37.4% YoY
5:00 PM ET 8-K
Financial Results Dolphin Entertainment, Inc. DLPN

Dolphin Entertainment Financial Results

Dolphin Entertainment reported record quarterly revenue of $16.0 million for Q3 2026, an 8.3% year-over-year increase. The company achieved profitability with net income of $0.2 million and a 42.9% increase in Adjusted EBITDA to $1.6 million, driven by organic growth and improved operating leverage.

Term
Q3 2026

“Dolphin had an outstanding third quarter. Revenue for the quarter grew 8.3% year-over-year to $16.0 million, the highest quarterly revenue in Dolphin’s history, even including Q1 2024 when we reported $3.4 million from Blue Angels.”

Bill O’Dowd, CEO of Dolphin

“We reported net income of $0.2 million, compared to a net loss of $0.4 million a year ago, and adjusted EBITDA increased 42.9% to $1.6 million versus $1.1 million a year ago.”

Bill O’Dowd, CEO of Dolphin
4:59 PM ET 10-Q
Financial Results Goldman Sachs Private Middle Market Credit II LLC

Goldman Sachs Private Middle Market Credit II Q3 2026 Results: Net Income $2.65M, Down 83.7% YoY

For the nine months ended September 30, 2026, Goldman Sachs Private Middle Market Credit II LLC reported total investment income of $113.26 million and net investment income of $70.61 million. The company experienced significant net unrealized depreciation of $55.19 million across its investment portfolio, contributing to a net asset value per unit of $65.20 compared to $68.62 at the end of 2025.

Key figure
Net income $2.65M · -83.7% YoY
4:59 PM ET 10-Q
Financial Results U.S. GoldMining Inc. USGO

U.S. GoldMining Q3 2026 Results: Net Loss of $8.19M, Loss Widens

U.S. GoldMining Inc. reported a significant increase in net loss to $14.3 million for the nine months ended September 30, 2026, compared to $5.0 million in the prior year, primarily driven by a surge in exploration expenses at the Whistler Project. The company remains in the exploration stage with no revenue, relying on equity financing including At-The-Market and registered direct offerings to fund its operations.

Key figure
Net loss $8.19M
4:59 PM ET 10-Q
Financial Results Netlist Inc NLST ▶ Call

Netlist Q3 2026 Results: Turns Profitable, Net Income $85.4M

Netlist reported a significant increase in net sales to $105.1 million for the third quarter of 2026, driven by a $44.9 million license fee and strong product sales. The company achieved a net income of $85.4 million for the quarter, aided by a $44.0 million income tax benefit and a substantial increase in deferred revenue.

Key figure
Net income $85.4M
4:58 PM ET 10-Q
Financial Results Resideo Technologies, Inc. REZI ▶ Call

Resideo Technologies Q3 2026 Results: Net Income $22M, Down 85.9% YoY

Resideo Technologies reported a net income of $22 million for the third quarter of 2026, a significant decrease from $156 million in the prior year period. The company completed the ADI Spin-Off during the period, resulting in a substantial reduction in total assets from $8.4 billion to $4.1 billion and a shift to a retained deficit of $1.4 billion.

Key figure
Net income $22M · -85.9% YoY
4:58 PM ET 10-Q
Financial Results Veradermics, Inc MANE

Veradermics Q3 2026 Results: Net Loss of $21M, Loss Widens

Veradermics, Inc. is a clinical-stage biopharmaceutical company focused on developing VDPHL01 for pattern hair loss. As of November 5, 2026, the company had 42,195,472 shares of common stock outstanding and continues to incur substantial losses with no products yet approved for commercial sale.

Key figure
Net loss $21M
4:56 PM ET 10-Q
Financial Results Apollo Origination II (UL) Capital Trust

Apollo Origination II Q3 2026 Results: Net Income $14.7M, Up 12.8% YoY

Apollo Origination II (UL) Capital Trust reported total investment income of $44.87 million for the nine months ended September 30, 2026, compared to $34.44 million in the prior year period. Net asset value per share decreased slightly to $25.39 from $25.55 at year-end 2025, primarily driven by net change in unrealized losses on investments.

Key figure
Net income $14.7M · +12.8% YoY
4:56 PM ET 10-Q
Financial Results Gevo, Inc. GEVO ▶ Call

Gevo Q3 2026 Results: Turns Profitable, Net Income $22.7M

Gevo, Inc. reported a significant net loss of $172.5 million for the nine months ended September 30, 2026, primarily driven by a $135.8 million impairment of long-lived assets and a $40.3 million allowance for credit losses. Despite these charges, total revenues grew to $172.4 million compared to $115.2 million in the prior year period, and the company generated positive cash flow from operations of $12.0 million.

Key figure
Net income $22.7M
4:55 PM ET 10-Q
Financial Results Apollo Origination II (Levered) Capital Trust

Apollo Origination II Q3 2026 Results: Net Income $21.3M, Up 13.4% YoY

For the nine months ended September 30, 2026, Apollo Origination II (Levered) Capital Trust reported total investment income of $101.9 million and net investment income of $51.3 million. Total net assets grew to $835.9 million, driven by $105 million in net proceeds from common share issuances, despite a net change in unrealized losses of $12.4 million during the period.

Key figure
Net income $21.3M · +13.4% YoY
4:53 PM ET 10-Q
Financial Results T Series BDC LLC

T Series BDC Q3 2026 Results: Net Income $9.25M, Down 59.7% YoY

T Series BDC LLC's Form 10-Q for the period ended September 30, 2026, details its financial performance and investment activity as a business development company. The filing highlights net investment income, changes in net assets from operations, and the current fair value of its private debt and equity portfolio.

Key figure
Net income $9.25M · -59.7% YoY
4:52 PM ET 10-Q
Financial Results Petmed Express Inc PETS

Petmed Express Q2 2026 Results: Net Loss of $6.43M, Loss Narrows

PetMed Express reported a significant decline in net sales of 19.6% for the six months ended September 30, 2026, resulting in a net loss of $12.6 million. Management identified substantial doubt about the company's ability to continue as a going concern due to declining cash balances and ongoing operating losses, though they believe strategic cost reductions and marketing optimizations will alleviate these concerns.

Key figure
Net loss $6.43M
4:51 PM ET 8-K
Financial Results Gossamer Bio, Inc. GOSS

Gossamer Bio Financial Results

Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.

Term
Q3 2026

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”

Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.